NCT03122548View on ClinicalTrials.gov

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

December 27, 2017

Study Completion Date

January 31, 2018

Conditions
Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
Interventions
BIOLOGICAL

CRS-207

Administered by IV infusion over 1 hour.

BIOLOGICAL

Pembrolizumab

Administered by IV infusion over 30 minutes.

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

21287

Johns Hopkins University, Baltimore

48202

Henry Ford Hospital, Detroit

60637

University of Chicago Medical Center, Chicago

75230

Mary Crowley Cancer Research, Dallas

80045

University of Colorado, Aurora

90095

UCLA Medical Center, Los Angeles

98101

Virginia Mason Medical Center, Seattle

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Aduro Biotech, Inc.

INDUSTRY

NCT03122548 - Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers | Biotech Hunter | Biotech Hunter